Complement and contact activation in term neonates after fetal acidosis

Josef Sonntag, Mathias H Wagner, Evelyn Strauss, Michael Obladen

Abstract

Aims—To evaluate complement and contact activation after fetal acidosis.

Methods—Fifteen term neonates with hypoxic–ischaemic encephalopathy after umbilical arterial pH < 7.10 were compared with 15 healthy neonates with umbilical arterial pH > 7.20. Determinations of the complement function and C1-inhibitor activity were performed as kinetic tests 22–28 hours after birth. C1q, C1-inhibitor, and factor B concentrations were determined by radial immunodiffusion and those of C3a, C5a, and factor XIIa by enzyme immunoabsorbent assay.

Results—Median complement function (46 vs 73 %), C1q (4.3 vs 9.1 mg/dl), and factor B (5.2 vs 7.7 mg/dl) decreased after fetal acidosis. The activated split products C3a (260 vs 185 µg/l), C5a (5.0 vs 0.6 µg/l), and factor XIIa (3.2 vs 1.3 µg/l) increased in the neonates after fetal acidosis. No differences were found in the concentration and activity of C1-inhibitor.

Conclusions—Complement and contact activation occurred in the newborns with hypoxic–ischaemic encephalopathy. Activation of these systems generates mediators which can trigger inflammation and tissue injury.

Keywords: birth asphyxia; complement activation; contact activation; fetal acidosis

The complement and contact systems are activated after ischaemia and reperfusion injury, for example, myocardial infarction, cardiac surgery with cardiopulmonary bypass, or liver transplantation. Fetal acidosis, as a marker for uteroplacental insufficiency, is associated with hypoxia and reperfusion injury in neonates. Complement and contact components in these babies have not been systematically investigated.

This study aimed to assess complement and contact system activation in term neonates with hypoxic–ischaemic encephalopathy after fetal acidosis by examining several complement components and factor XIIa (Hageman factor) in the neonates after fetal acidosis. Fifteen healthy term neonates without perinatal complications, with the same gestational age, and an umbilical arterial pH > 7.20 were enrolled in the control group at the same time.

The study group were monitored to maintain mean arterial blood pressure, body temperature, normoglycaemia, normocalcaemia, normoxaemia, and normocapnia. Therapeutic interventions included infusion of fluids, mechanical ventilation, and administration of glucose and calcium. Five infants with convulsions were treated with phenobarbital, three received erythrocyte transfusion because of anaemia within the first 24 hours. Eleven infants were given pasteurised plasma solutions (Biseko, Biotest, Dreieich, Germany) for volume expansion. None of the patients received dexamethasone.

Blood samples were taken 22–28 hours after birth. Samples of blood (0.4 ml) were collected in two tubes containing either disodium-ethylene diamine tetra acetic acid (EDTA; Kabi-Labortechnik, Germany) or 0.07 ml sodium citrate (Fa; Saarstedt, Germany) and within 20 minutes centrifuged for 5 minutes at 3000 rpm. The plasma was immediately

Figure 1 Complement system activation.
The study group showed decreased functional activity of the whole complement system as well as decreased plasma concentrations of C1q and factor B. Higher amounts of activated split products C3a, C5a and factor XIIa were found in this group than in the control group. No difference in concentration or functional activity of C1-inhibitor was found between the study and control groups (table 2).

Discussion

Brain damage after severe fetal acidosis may affect the entire life of the child. Many studies have investigated the pathophysiology of the developing tissue injury based on hypoxia and ischaemia and its therapeutic prevention in affected neonates. A primary problem is to determine the coefficients of variation were within the normal range for neonatal plasma. C3a enzyme immunoassay (EIA, Fa. Progen Biotechnik GmbH, Heidelberg, Germany) selectively detects C3a-desArg using monoclonal antibodies.11 The variation coefficient (n = 20) for a concentration of 550 µg/l was 8% for this method. C5a was determined using a specific sandwich EIA (Fa. Behring, Marburg, Germany) and showed a variation coefficient (n = 20) of 8% for a concentration of 5 µg/l.12

The concentration of activated factor XIIa was measured using a semiquantitative direct immunooassay with specific sheep monoclonal antibodies (WAK-Chemie Medical GmbH, Bad Homburg, Germany).13 The intra-assay coefficient of variation (n = 20) for a concentration of 10 µg/l was 6%.

The functional activity of the C1-inhibitor was determined in citrated plasma by using the chromogenic substrate technique described by Heber et al (Behring Diagnostica AG, Marburg, Germany).14 The coefficient of variation in an intra-assay precision study for a standard plasma with an activity of 95% was 5%.

As most of the data were not distributed normally, results were expressed as medians with quartiles. Differences between the two groups were assessed using the Mann-Whitney U test. Significance was assumed at p < 0.05. All calculations and tests were carried out using the software package SPSS-PC (Chicago, Illinois USA).

Results

Clinical data from the study and control group are shown in table 1. Ten neonates from the study group developed grade I hypoxic–ischaemic encephalopathy, three grade II, and two grade III. Five neonates from the study group had renal failure in the first 48 hours, characterised by diuresis <1.0 ml/kg/hour and serum creatinine >120 µmol/l. Four developed a coagulation disorder in the first three days of life. Nine neonates were intubated at birth and artificially ventilated for 0.5 to 168 hours, two of them developed clinical and radiological signs of surfactant deficiency. None of the infants died before being discharged from hospital. None of the infants from the control group had clinical symptoms of hypoxic–ischaemic encephalopathy, respiratory distress, coagulation disorders, or renal failure.

The study group showed decreased functional activity of the whole complement system as well as decreased plasma concentrations of C1q and factor B. Higher amounts of activated split products C3a, C5a and factor XIIa were found in this group than in the control group. No difference in concentration or functional activity of C1-inhibitor was found between the study and control groups (table 2).
Complement and contact activation in term neonates after fetal acidosis

F127

plasma.4 Considering the increased anaphylatoxin molecules were found in binds to granulocyte receptors and only the enhanced production, because C5a first without (n=13) respiratory distress syndrome. The increased C5aafter fetal acidosis indicates the immune system. Thus the main function and concentration of native proteins, we assumed that the complement system is activated after birth acidosis. Because the complement activation was evident 22 to 28 hours after birth, the effect of therapeutic interventions on the complement system activation within this time frame cannot be excluded. However, we found no differences between the infants who were treated with phenobarbital, transfusion, or pasteurised plasma solutions and those who were not in the study group. None of the study infants received drugs or acute interventions that are reported to influence the immune system. Thus the main reason for the complement activation is probably cell disintegration. Ischaemia releases subcellular constituents—mostly mitochondrial proteins—which bind to C1q and activate the complement cascade in vitro and in vivo.20 21 Another reason for complement activation is the loss of protective membrane proteins on injured cells, which may be due to the activation of complement cascade in the ischaemic area.22 23

The complement system has a major role in initiating some of the inflammatory events occurring in ischaemia and reperfusion after myocardial infarction, cardiopulmonary bypass surgery, and liver transplantation.1 4 23 Anaphylatoxins contribute to an increased permeability of small blood vessels, the contraction of smooth muscles, the release of histamine, the secretion of lysosomal enzymes and cytokines as well as granulocyte migration and adher-

dence. Another aspect of the complement activation is the direct cytotoxic effect of the membrane attack complex on endothelial cells.5 All these mechanisms may enhance tissue injury following ischaemia and reperfusion.22 25 26

The increased concentrations of factor XIIa in the study group may be explained by contact activation after fetal acidosis. The reason for this activation likely is the contact of factor XII with negatively charged surfaces or cell constituents after cell destruction. Additionally, the contact system is activated by hypoxanthine,27 which increases after birth asphyxia.28 The activated contact or kinin system is involved in inflammatory tissue injury through bradykinin and kallikrein release with increased vascular permeability, leucocyte accumulation, and arterial hypotension. The contact system is closely related to the complement system, and mutual activation is possible.29 Additionally, factor XIIa influences coagulation and fibrinolysis,27 which act simultaneously after birth asphyxia.29 Thus increased values of factor XIIa can contribute to the development of disseminated intravascular coagulation disorders in acidotic neonates.

Activation of the complement and contact system has major pathophysiological effects including some of the inflammatory events occurring in myocardial infarction, cardiopulmonary bypass surgery, and liver transplantation.1 4 23 Another reason for contact activation is the loss of protective membrane proteins on injured cells. However, we found no differences between the infants who were treated with phenobarbital, transfusion, or pasteurised plasma solutions and those who were not in the study group. None of the study infants received drugs or acute interventions that are reported to influence the immune system. Thus the main reason for the complement activation is probably cell disintegration. Ischaemia releases subcellular constituents—mostly mitochondrial proteins—which bind to C1q and activate the complement cascade in vitro and in vivo.20 21 Another reason for complement activation is the loss of protective membrane proteins on injured cells, which may be due to the activation of complement cascade in the ischaemic area.22 23

The complement system has a major role in initiating some of the inflammatory events occurring in ischaemia and reperfusion after myocardial infarction, cardiopulmonary bypass surgery, and liver transplantation.1 4 23 Anaphylatoxins contribute to an increased permeability of small blood vessels, the contraction of smooth muscles, the release of histamine, the secretion of lysosomal enzymes and cytokines as well as granulocyte migration and adher-

9 Kolde HJ, Deuel R. Development of a rapid kinetic assay for the function of the classical pathway of the complement system.

This work was supported by the German Research Society (DFG-Ob 43/6-2).
Complement and contact activation in term neonates after fetal acidosis

Josef Sonntag, Mathias H Wagner, Evelyn Strauss and Michael Obladen

Arch Dis Child Fetal Neonatal Ed 1998 78: F125-F128
doi: 10.1136/fn.78.2.F125

Updated information and services can be found at:
http://fn.bmj.com/content/78/2/F125

These include:

References
This article cites 27 articles, 4 of which you can access for free at:
http://fn.bmj.com/content/78/2/F125#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
Metabolic disorders (291)
Immunology (including allergy) (393)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/